MD Anderson Cancer Center-University of Texas
Welcome,         Profile    Billing    Logout  
 7 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Michael
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Recruiting
3
71
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors

Recruiting
2
12
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B With Inhibitor, Hemophilia B
09/25
10/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
ONCT-808-101, NCT05588440: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Recruiting
1/2
57
US
ONCT-808, Bridging Therapy
Oncternal Therapeutics, Inc
Relapsed/Refractory Aggressive B-Cell Malignancies
12/26
12/37
VISTA, NCT05619471: VIO Imaging for Skin Tissue Assessment

Completed
N/A
65
US
VIO Imaging
Enspectra Health, National Cancer Institute (NCI), National Institutes of Health (NIH)
Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer
08/23
08/23
NCT03853486: ATHN 9: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting
N/A
120
Europe, Canada, US
Non-Interventional
Regeneron Pharmaceuticals
Hemophilia B
04/26
04/26
Addison, Alicia
No trials found

Download Options